Sialyl Lewis a

General | Antibody | Glycoprotein | Glycolipid | Enzyme | Reference

Epitope information of EP0008

Epitope IDEP0008
Epitope nameSialyl Lewis a
AliasesSialyl Lea ,carbohydrate antigen 19-9 / CA19-9
HistorySialyl Lea was characherized as a tumor marker.[9*]
The term Lewis refers to the family name of individuals suffering from a red blood cell incompatibility problem that helped lead to the discovery of this blood group.
DB GlyTouCan:G00053MO JCGGDB
Molecular weight820.8

Homo sapiens

Tissue and Cellular distribution

Subcellular distribution

Developmental change

In normal tissues,Sialyl Lea antigen is expressed in biliary and pancreatic duct epithelia.[4]
Sialyl Lea is expressed in many malignant cells.[5]

Cell line

B16/mouse melanoma
BxPC-3/human pancreatic carcinoma
COLO 205/human colon adenocarcinoma
HL-60/human promyelocytic leukemia
HT-29/human colon adenocarcinoma
HT-29LMM/metastatic parental




The carbohydrate determinants,Sialyl Lea and Sialyl Lex,which are frequently expressed on human cancer cells,serve as ligands for a cell adhesion molecule of the selectin family,E-selectin,which is expressed on vascular endothelial cells. These carbohydrate determinants are involved in the adhesion of cancer cells to vascular endothelium and thus contribute to hematogenous metastasis of cancer.[3]


pancreatic adenocarcinoma
hepatocellular cancer
cholangiocellular cancer
gastric cancer
colorectal cancer[24]
ovarian cancer
lung cancer
breast cancer
uterine cancer

CA 19-9 is detected with highest levels in excretory ductal pancreatic adenocarcinoma, biliary, hepatocellular and cholangiocellular cancer besides gastric, colorectal and ovarian cancer and occasionally in lung, breast and uterine cancer.[2]

ApplicationThe monoclonal antibody NS 19-9 is a representative diagnostic agent for pancreatic adenocarcinoma and cholangiocellular cancer.

Mucins and BGM (bile globular membrane)(see Reference) are CA19-9 carriers in sera of patients with cancer.[25]